🇮🇳·14h agoIndustry
natco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26
Publisher
N
Natco Pharma
India
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Natco Pharma
- Region
- India
- Scope
- Industry
- Published
- July 16, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on natcopharma.co.in
Leave the platform to read the original full article on the publisher site.
Source: Natco Pharma
Scope: Industry
Related coverage
More related coverage
Merck & Co. (MSD) News/3h ago
Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia
Eli Lilly News/3h ago
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
Recordati/5h ago
On behalf of Respighi BidCo S.p.A – Press Release pursuant to Article 36 of the Issuers’ Regulation
Ipsen/6h ago